文献速递浆细胞疾病

R2-ISS风险分层在UAMS接受自体干细胞移植的多发性骨髓瘤患者中的应用

Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
PubMed 文献 · Blood Adv · 2023-01-01

该研究纳入2001至2021年间在UAMS接受 upfront 自体干细胞移植的860例多发性骨髓瘤患者,中位年龄60岁,中位总生存123个月,中位无进展生存70个月。ISS、R-ISS和R2-ISS三种分期系统在总生存和无进展生存方面均表现出稳健的区分能力,R2-ISS进一步将患者分为4个更均衡的风险组。在低风险R2-ISS I/II期和高风险III/IV期中,年龄、血红蛋白、1p缺失、血清轻链、血小板计数和t(14;16)易位分别影响风险分类。

要点

  • R2-ISS在860例自体移植多发性骨髓瘤患者中可区分4个风险组,对OS和PFS均有稳健区分能力。
  • 低风险R2-ISS I/II期中,年龄、血红蛋白和1p缺失显著影响患者分类。
  • 高风险R2-ISS III/IV期中,血清轻链、血小板计数、年龄和t(14;16)易位影响分类。

核心结论

  • ISS、R-ISS和R2-ISS三种分期系统在总生存和无进展生存方面均表现出稳健的区分能力,R2-ISS进一步将患者分为4个更均衡的风险组。

研究设计与样本

  • 研究纳入2001年至2021年间在UAMS接受 upfront 自体干细胞移植的860例多发性骨髓瘤患者,中位年龄60岁。
  • 收集ISS、R-ISS和R2-ISS系统包含的变量以及额外的标准变量。

主要发现

  • 整个队列中位总生存为123个月,中位无进展生存为70个月。
  • ISS系统将患者有效分为3个风险组,R-ISS系统准确识别极高危或低危患者。
  • R2-ISS系统进一步将患者分为4个更均衡的风险组。
  • 在低风险R2-ISS I/II期中,年龄、血红蛋白和1p缺失显著影响患者分类。
  • 在高风险R2-ISS III/IV期中,血清轻链、血小板计数、年龄和t(14;16)易位的存在影响分类。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Second Revision of the International Staging System (R2-ISS) was published in 2022 and has been validated in several cohorts of patients with multiple myeloma (MM). In this study, we investigated a total of 860 patients with MM who received an upfront autologous stem cell transplantation between 2001 and 2021. The median age of the patients was 60 years, with a median overall survival (OS) of 123 months and median progression-free survival (PFS) of 70 months. We collected the variables included in the ISS, R-ISS, and R2-ISS systems as well as additional standard variables. Our analyses demonstrated that all 3 ISS series systems (ISS, R-ISS, and R2-ISS) exhibited robust discrimination in terms of both OS and PFS among our study cohort. The ISS system effectively stratified patients into 3 risk groups, whereas the R-ISS system accurately identified patients at extremely high or low risk. The R2-ISS system further refined risk stratification by dividing patients into 4 more balanced risk groups. Furthermore, we specifically focused on identifying variables that distinguished patients with OS < 3 years and OS > 10 years within the low-risk R2-ISS stages (I and II) and high-risk R2-ISS stages (III and IV). Our findings revealed that age, hemoglobin, and 1p deletion significantly influenced the classification of patients in the low-risk R2-ISS stage. Additionally, serum light chain, platelet count, age, and the presence of the t(14;16) translocation were found to affect high-risk classification.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Guo W, Zhan A, Mery DE, et al. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood Adv. 2023. PMID: 37756524. doi:10.1182/bloodadvances.2023011096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。